A BILL 
To amend title XXVII of the Public Health Service Act 
to improve patient access to anti-cancer oral medications, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Timely Access to Can-
4
cer Treatment Act of 2021’’ or the ‘‘TACT Act of 2021’’. 
5
SEC. 2. PATIENT ACCESS TO ANTI-CANCER ORAL MEDICA-
6
TIONS. 
7
(a) IN GENERAL.—Section 2719A of the Public 
8
Health Service Act (42 U.S.C. 300gg–19A) is amended 
9
by adding at the end the following new subsection: 
10
01:56 Jul 01, 2021
H3258
2 
•HR 3258 IH
‘‘(f) ACCESS
TO
ANTI-CANCER
ORAL
MEDICA-
1
TIONS.— 
2
‘‘(1) REQUIREMENTS
FOR
CONTRACTS
BE-
3
TWEEN GROUP HEALTH PLANS OR HEALTH INSUR-
4
ANCE ISSUERS AND PHARMACIES.—If a group health 
5
plan or a health insurance issuer offering group or 
6
individual health insurance coverage covers or pro-
7
vides any benefits for anti-cancer oral medications 
8
(as defined in paragraph (4)) and enters into a con-
9
tract with a pharmacy, whether directly or through 
10
an agent of such plan or issuer (including a phar-
11
macy benefit manager), to dispense such medications 
12
to participants, beneficiaries, or enrollees of the plan 
13
or coverage, such plan or issuer shall require, as 
14
conditions of such contract, such pharmacy to carry 
15
out the procedures described in paragraph (2). 
16
‘‘(2) PROCEDURES DESCRIBED.—For purposes 
17
of paragraph (1), the procedures described in this 
18
paragraph with respect to a participant, beneficiary, 
19
or enrollee of the plan or coverage and a health care 
20
provider who submits to such pharmacy a prescrip-
21
tion for an anti-cancer oral medication for such par-
22
ticipant, beneficiary, or enrollee are the following (as 
23
applicable): 
24
01:56 Jul 01, 2021
H3258
3 
•HR 3258 IH
‘‘(A) PHARMACY CONFIRMATION OF ABIL-
1
ITY TO DISPENSE.—Not later than 24 hours 
2
after receiving such prescription— 
3
‘‘(i) confirm to such health care pro-
4
vider that such pharmacy received such 
5
prescription; and 
6
‘‘(ii) inform such health care provider, 
7
as well as such plan or issuer, whether 
8
such pharmacy will dispense such anti-can-
9
cer oral medication to such participant, 
10
beneficiary, or enrollee by not later than 
11
72 hours after receiving such prescription, 
12
including any time for benefits verification, 
13
prior authorization, or any other adminis-
14
trative procedure required by the agent of 
15
such plan or issuer (including a pharmacy 
16
benefit manager) prior to authorizing the 
17
pharmacy to dispense the medication. 
18
‘‘(B) PHARMACY ABLE TO FILL PRESCRIP-
19
TION.—In the case that such pharmacy informs 
20
such health care provider in writing under sub-
21
paragraph (A)(ii) that such pharmacy is able to 
22
dispense such anti-cancer oral medication to 
23
such participant, beneficiary, or enrollee by the 
24
72-hour deadline described in such subpara-
25
01:56 Jul 01, 2021
H3258
4 
•HR 3258 IH
graph, dispense such anti-cancer oral medica-
1
tion to such participant, beneficiary, or enrollee 
2
by such deadline. 
3
‘‘(C) PHARMACY
UNABLE
TO
FILL
PRE-
4
SCRIPTION.—In the case that such pharmacy 
5
informs such health care provider under sub-
6
paragraph (A)(ii) that such pharmacy is not 
7
able to dispense such anti-cancer oral medica-
8
tion to such participant, beneficiary, or enrollee 
9
by the 72-hour deadline described in such sub-
10
paragraph, immediately provide a written notice 
11
to— 
12
‘‘(i) the prescribing physician or other 
13
health care provider; 
14
‘‘(ii) the group health plan or a health 
15
insurance issuer offering group or indi-
16
vidual health insurance coverage; and 
17
‘‘(iii) such participant, beneficiary, or 
18
enrollee; 
19
with a clear and understandable explanation of 
20
such inability and of the option of such partici-
21
pant, beneficiary, or enrollee to be dispensed 
22
such anti-cancer oral medication from any pro-
23
vider or pharmacy described in paragraph 
24
(3)(C), in accordance with the cost-sharing re-
25
01:56 Jul 01, 2021
H3258
5 
•HR 3258 IH
quirements described in subparagraphs (A) and 
1
(B) of such paragraph. 
2
‘‘(D) PHARMACY
FAILURE
TO
COMMU-
3
NICATE.—If the pharmacy does not commu-
4
nicate its ability to dispense as required by sub-
5
paragraph (A), or, after confirming that it will 
6
dispense an anti-cancer oral medication under 
7
such subparagraph, does not actually dispense 
8
such medication by the 72-hour deadline de-
9
scribed in such paragraph, such pharmacy shall 
10
be deemed to have confirmed that it is not able 
11
to dispense such medication under subpara-
12
graph (C). 
13
‘‘(3) REQUIREMENTS
FOR
GROUP
HEALTH 
14
PLANS AND HEALTH INSURANCE ISSUERS.— 
15
‘‘(A) PATIENT SELECTION OF ALTERNATE 
16
PROVIDER OR PHARMACY.—If a group health 
17
plan or a health insurance issuer offering group 
18
or individual health insurance coverage (or its 
19
agent, including a pharmacy benefits manager) 
20
described in paragraph (1) enters into a con-
21
tract described in such paragraph, with a phar-
22
macy and such pharmacy, with respect to a 
23
participant, beneficiary, or enrollee of the plan 
24
or coverage and health care provider who sub-
25
01:56 Jul 01, 2021
H3258
6 
•HR 3258 IH
mits to such pharmacy a prescription for an 
1
anti-cancer oral medication for such partici-
2
pant, beneficiary, or enrollee, informs such 
3
health care provider under subparagraph (A)(ii) 
4
of such paragraph that such pharmacy will not 
5
dispense such anti-cancer oral medication to 
6
such participant, beneficiary, or enrollee by the 
7
72-hour deadline described in such subpara-
8
graph (or in the case that the participant, bene-
9
ficiary, or enrollee has not received the anti- 
10
cancer oral medication by the 72-hour dead-
11
line), the plan or issuer— 
12
‘‘(i) shall authorize such participant, 
13
beneficiary, or enrollee to select any pro-
14
vider or pharmacy described in subpara-
15
graph (C) to dispense such anti-cancer oral 
16
medication to such participant, beneficiary, 
17
or enrollee based on the written noticed de-
18
scribed in paragraph (2)(C) or a certifi-
19
cation by the prescribing physician or 
20
other health professional that the partici-
21
pant, beneficiary, or enrollee has not re-
22
ceived the anti-cancer oral medication by 
23
the 72-hour deadline; and 
24
01:56 Jul 01, 2021
H3258
7 
•HR 3258 IH
‘‘(ii) in the case the provider or phar-
1
macy selected under clause (i) does not 
2
have a contract with such plan or issuer to 
3
dispense such anti-cancer oral medication 
4
to such participant, group health plan or 
5
health insurance issuer offering group or 
6
individual health insurance coverage de-
7
scribed in paragraph (1) shall cover the 
8
medication and pay the provider or phar-
9
macy in accordance with the provisions of 
10
subparagraph (B). 
11
‘‘(B) COVERAGE REQUIREMENTS FOR PRE-
12
SCRIPTIONS
DISPENSED
BY
ALTERNATE
PRO-
13
VIDER OR PHARMACY.—For prescriptions dis-
14
pensed by an alternate provider or pharmacy in 
15
accordance with subparagraph (A) that does 
16
not have a contract with a group health plan or 
17
a health insurance issuer offering group or indi-
18
vidual health insurance coverage (or its agent, 
19
including a pharmacy benefits manager) de-
20
scribed in paragraph (1) to dispense such anti- 
21
cancer oral medication to such participant, such 
22
group health plan or a health insurance issuer 
23
(or its agent, including a pharmacy benefits 
24
manager) shall cover the medication and pay 
25
01:56 Jul 01, 2021
H3258
8 
•HR 3258 IH
the provider or pharmacy subject the following 
1
requirements— 
2
‘‘(i) such medication will be provider 
3
without imposing any requirement under 
4
the plan for prior authorization of the 
5
medication or any limitation on coverage 
6
that is more restrictive than the require-
7
ments or limitations that apply to anti-can-
8
cer oral medications received from partici-
9
pating providers and pharmacies with re-
10
spect to such plan; 
11
‘‘(ii) the cost-sharing requirement (ex-
12
pressed as a copayment amount or coinsur-
13
ance rate) is not greater than the require-
14
ment that would apply if such services 
15
were provided by a participating provider 
16
or a participating pharmacy; 
17
‘‘(iii) such cost-sharing requirement is 
18
calculated as if the total amount that 
19
would have been charged for such services 
20
by such participating provider or partici-
21
pating pharmacy were equal to the recog-
22
nized amount (as determined by the Sec-
23
retary) for such anti-cancer oral medica-
24
tions, plan, and year; 
25
01:56 Jul 01, 2021
H3258
9 
•HR 3258 IH
‘‘(iv) the group health plan pays to 
1
such provider or pharmacy, respectively, 
2
the amount by which the recognized 
3
amount for such services and year involved 
4
exceeds the cost-sharing amount for such 
5
services (as determined in accordance with 
6
clauses (ii) and (iii)) and year; 
7
‘‘(v) any cost-sharing payments made 
8
by the participant or beneficiary with re-
9
spect to such anti-cancer oral medication 
10
so furnished shall be counted toward any 
11
in-network 
deductible 
or 
out-of-pocket 
12
maximums applied under the plan (and 
13
such in-network deductible and out-of- 
14
pocket maximums shall be applied) in the 
15
same manner as if such cost-sharing pay-
16
ments were made with respect to anti-can-
17
cer oral medication furnished by a partici-
18
pating provider or a participating phar-
19
macy; and 
20
‘‘(vi) such medication will be provided 
21
without regard to any other term or condi-
22
tion of such coverage (other than exclusion 
23
or coordination of benefits, or an affiliation 
24
or waiting period, permitted under section 
25
01:56 Jul 01, 2021
H3258
10 
•HR 3258 IH
2704 of this Act, including as incorporated 
1
pursuant to section 715 of the Employee 
2
Retirement Income Security Act of 1974 
3
and section 9815 of this Act, and other 
4
than applicable cost-sharing). 
5
‘‘(C) 
PROVIDER
OR
PHARMACY
DE-
6
SCRIBED.—A provider or pharmacy described in 
7
this subparagraph, with respect to a partici-
8
pant, beneficiary, or enrollee of a group health 
9
plan or group or individual health insurance 
10
coverage described in paragraph (1) and a pre-
11
scription for an anticancer oral medication for 
12
such participant, beneficiary or enrollee, is a 
13
provider or pharmacy that— 
14
‘‘(i) is licensed by the State in which 
15
such provider or pharmacy is located to 
16
dispense such anti-cancer oral medication, 
17
if such a license is required by the State; 
18
‘‘(ii) is either located within a reason-
19
able distance (as determined by the Sec-
20
retary) of the residence of such partici-
21
pant, beneficiary, or enrollee, or is able to 
22
deliver such anti-cancer oral medication to 
23
such participant, beneficiary, or enrollee at 
24
such residence; and 
25
01:56 Jul 01, 2021
H3258
11 
•HR 3258 IH
‘‘(iii) is able to dispense (and if appli-
1
cable, deliver), such anti-cancer oral medi-
2
cation to such participant, beneficiary, or 
3
enrollee within 48 hours of the date on 
4
which it receives the prescription. 
5
For purposes of this section, a provider or 
6
pharmacy described in this subparagraph in-
7
cludes a physician or other health care practi-
8
tioner authorized to dispense anti-cancer oral 
9
medication to such participant, beneficiary, or 
10
enrollee pursuant to the law of the State in 
11
which the physician or other health care practi-
12
tioner is located. 
13
‘‘(D) PRIOR
AUTHORIZATION
REQUIRE-
14
MENTS.—In the case of a group health plan or 
15
a health insurance issuer offering group or indi-
16
vidual health insurance coverage that requires 
17
prior authorization for an anti-cancer oral 
18
medication to be dispensed to a participant, 
19
beneficiary, or enrollee of the plan or coverage, 
20
such plan or issuer (or its agent , including a 
21
pharmacy benefits manager) shall make a deci-
22
sion with respect to a request for such a prior 
23
authorization by not later than 72 hours after 
24
receiving such request. In the case that such 
25
01:56 Jul 01, 2021
H3258
12 
•HR 3258 IH
plan or issuer (or its agent, including a phar-
1
macy benefits manager) does not make a deci-
2
sion with respect to a request for prior author-
3
ization for an anticancer oral medication to be 
4
dispensed to a participant, beneficiary, or en-
5
rollee of the plan or coverage by the 72-hour 
6
deadline described in the previous sentence, 
7
such participant, beneficiary or enrollee may se-
8
lect any pharmacy described in subparagraph 
9
(C) to dispense such anticancer oral medication 
10
to such participant, beneficiary, or enrollee, in 
11
accordance with the cost-sharing requirements 
12
described in subparagraph (B) but only if the 
13
prescription for such anti-cancer oral medica-
14
tion meets the clinical guidelines set forth by 
15
the National Comprehensive Cancer Network. 
16
‘‘(4) ANTI-CANCER
ORAL
MEDICATION
DE-
17
FINED.—In this subsection, the term ‘anti-cancer 
18
oral medication’ means a drug or biological (as de-
19
fined in section 1861(t) of the Social Security Act) 
20
that is used in an anti-cancer chemotherapeutic regi-
21
men for a medically accepted indication, including 
22
any related supportive care drugs and biologicals 
23
that are dispensed as an outpatient and taken by the 
24
mouth.’’. 
25
01:56 Jul 01, 2021
H3258
13 
•HR 3258 IH
(b) EFFECTIVE DATE.—The amendments made by 
1
this section shall apply with respect to plan years begin-
2
ning on or after January 1, 2022. 
3
(c) GAO REPORT AND RECOMMENDATIONS.— 
4
(1) IN GENERAL.—Not later than 2 years after 
5
the date of enactment of this Act, the Comptroller 
6
General of the United States shall submit to the 
7
Chair and Ranking Member of the Committee on 
8
Health, Education, Labor and Pensions of the Sen-
9
ate and the Chair and Ranking Member of the Com-
10
mittee on Energy and Commerce of the House of 
11
Representatives a report on the effects of the imple-
12
mentation of subsection (f) of section 2719A of the 
13
Public Health Service Act (as added by subsection 
14
(a)) on the timely access of patients to anti-cancer 
15
oral medications (as defined in subsection (f)(4) of 
16
such section), together with such recommendations 
17
as the Comptroller General determines are appro-
18
priate. 
19
(2) ITEMS INCLUDED.—The report submitted 
20
under paragraph (1) shall include— 
21
(A) a comparison of the amount of time 
22
between the date on which a prescription is 
23
written and the date on which a patient receives 
24
an anti-cancer oral medication before and after 
25
01:56 Jul 01, 2021
H3258
14 
•HR 3258 IH
the implementation of subsection (f) of section 
1
2719A of the Public Health Service Act; 
2
(B) an assessment of the effects on patient 
3
health outcomes, including morbidity and mor-
4
tality; 
5
(C) an evaluation of costs to patients, 
6
health insurance issuers, physicians, and other 
7
healthcare providers; and 
8
(D) a risk assessment with mitigation rec-
9
ommendations on any actual or potential fraud, 
10
waste and abuse relating to the implementation 
11
of such subsection. 
12
Æ 
01:56 Jul 01, 2021
H3258
